Please ensure Javascript is enabled for purposes of website accessibility

Why Gritstone Oncology Stock Is Sinking Today

By Keith Speights – Updated Apr 25, 2019 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pricing of a secondary stock offering is taking a toll on the biotech stock.

What happened

Shares of Gritstone Oncology (GRTS) were sinking by 12.9% as of 11:04 a.m. EDT on Thursday. The clinical-stage biotech announced yesterday the pricing of a public offering of 6.5 million shares of its stock at $11.50 per share.

So what

There were two reasons why Gritstone's secondary stock offering weighed on its share price today.

Gloved hands holding lab glassware with other test tubes and droppers in view.

Image source: Getty Images.

First, the price tag of that offering was 6.5% lower than the stock's closing price on Wednesday. Anytime a company announces that it's going to sell shares at a lower price than the current market price, you can count on the share price dropping.

Second, there's the dilution in the value of existing shares caused by Gritstone's stock offering. The biotech will soon have 6.5 million more shares in circulation. That's roughly 22% of Gritstone's total current outstanding shares.

The good news from the transaction, though, is that Gritstone will raise $74.8 million in additional capital before expenses are deducted. Gritstone reported cash, cash equivalents, and marketable securities totaling $153.1 million as of Dec. 31, 2018. With the biotech burning through around $18 million each quarter and its operating expenses rising, it made sense that Gritstone would seek an opportunity to boost its cash stockpile.

Now what

With more cash on hand, Gritstone Oncology should be well positioned to continue advancing the experimental immunotherapies in its pipeline. The company expects to begin a phase 1 clinical study evaluating SLATE-001, an "off-the-shelf" immunotherapy, in the second half of this year. Gritstone also anticipates reporting preliminary data from the phase 1a part of its clinical trial of GRANITE-001 personalized immunotherapy in the fourth quarter of 2019.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.